Potential to decrease INR; monitor INR and adjust warfarin dosage as needed to maintain the target INR range.
May increase the exposure of CYP1A2 substrates; monitor the drug concentrations of CYP1A2 substrates with a narrow therapeutic index.
Avoid concomitant use.If co-administration is deemed necessary, monitor serum transaminases and bilirubin.
FDA,2022.02